Introduction: HLA-mismatched unrelated cord blood transplantation (UCBT) is feasible and, in retrospective comparative analyses, allows survival rates similar to conventional unrelated HLA-matched adult-derived grafts. It is clear that the degree of UCB HLA mismatch in patients has a negative effect on outcomes with low-resolution HLA typing at A, B, DR. But the impact of HLA disparity on outcomes with high-resolution HLA typing HLA-A, -B, -C, -DR is unclear. Patients and Methods: To determine the impact of HLA disparity on outcomes after UCBT, We retrospectively reviewed patients with hematologic malignancies who underwent reduced intensity CBT at Toranomon Hospital from August 2006 and December 2010 consecutively. Patients who had prior history of transplantation, were in poor performance status (ECOG PS >3), had active bacterial or fungal infections at the time of conditioning were excluded. The most frequently used conditioning regimens were fludarabine, alkylating agent (melphalan or busulfan) with total body irradination (TBI), tacrolimus plus mycophenolate mofetil for GVHD prophylaxis. DNAs of 97 pairs were analysed for HLA-A, -B, -C, and -DRB1 based on High Resolution typing. In these cases high resolution typing was carried out retrospectively. Results: For HLA-A, -B, -C, and -DR based on high resolution typing the following mismatch occurred: no mismatch 2(2%), one mismatch 5(5%), two mismatch 14(14%), three mismatch 32(33%), four mismatch 28(29%), five mismatch 14(14%), six mismatch 2(2%). The number of total nucleated cells and CD34 + cells were not significantly different among them.
The cumulative incidence of neutrophil recovery was 83.5% in this study population. It was higher in HLA-B matched group than in HLA-B mismatched group ( 94.2% vs. 78.5% up to day 60, p¼0.0044), and in multivariate analysis HLA-B mismatch was independent predictor of engraftment (HR, 0.074; 95%CI, 0.0074-0.74; p¼0.026). Among the HLA-A, -C, -DRB1 mismatches, the negative impact of each single HLA allele mismatch was not significant.
The cumulative incidence of grade II to IV aGVHD in this study population was 52.6%. In multivariate analysis, HLA-A mismatch (HR, 10.51; 95%CI, 1.95-56.51; p¼0.0061), and HLA-B mismatch (HR, 51.59; 95%CI, 1.05-2520.0; p¼0.043) were significantly associated with high incidence of grade II-IV GVHD.
There were no significant difference in the cumulative incidence of TRM, Relapse Rate and OS in this study. Conclusion: HLA-B allele mismatch was found to have a significant negative impact on engraftment and II-IV aGVHD. The degree of antigen-level (HLA-A, -B) and allele-level HLA-DRB1 matching has been correlated with the risk of acute GVHD (aGVHD) in prior studies of umbilical cord blood transplantation (UCBT), however no impact of HLA matching on development of chronic GVHD (cGVHD) has been reported for 4/6-matched UCBT. To understand the impact of high-resolution HLA allele matching at -A, -B, -C, -DRB1 and -DQ loci on GVHD we studied 404 recipients of single-(n¼129) and double-unit (n¼275, based on the predominating unit) UCBT from 2000 to 2010. Overall cumulative incidence of grade II-IV aGVHD, grade III-IV aGVHD, and cGVHD was 47%, 18%, and 20%, respectively. HLA allele-matched recipients, grouped as 9-10/10 (17%), 6-8/10 (61%), and <6/10 (22%), had a similar cumulative incidence of grade II-IV (43% vs. 47% vs. 52%, p¼0.5) or grade III-IV (17% vs. 16% vs. 22%, p¼0.4) aGVHD, respectively. In multivariable analysis HLA matching did not influence grade II-IV and III-IV aGVHD (all p>0.5) after adjustment for the number of units, CD3, CD34 dose, age, gender match, conditioning, recipient CMV status, ATG use, and the year of transplant (Table) . Use of ATG was independently associated with a lower risk of grade II-IV aGVHD (relative risk [RR]¼ 0.5, p<0.01). Univariate difference in cumulative incidence of cGVHD for 9-10/10 (17%), 6-8/10 (17%), and <6/10 (29%) HLA match was confounded by age (RR¼3.4 for 18 years, p<0.01) and prior aGVHD (RR¼2.3, p<0.01) in multivariable analysis adjusted for CD34, CD3 dose, and the number of cord units. No other factors influenced cGVHD or modified the risk of HLA matching on cGVHD. Similar results were found in a multivariable analysis for stratified single-and double-unit UCBT. We conclude that stringent high-resolution HLA matching at -A, -B, -C, -DRB1 and -DQ loci does not influence the incidence of acute or chronic GVHD among recipients of UCBT. Relative risk* of acute and chronic GVHD based on degree of high-resolution HLA matching Factor RR of aGVHD (95% CI) RR of cGVHD (95% CI) (n¼79) Grade II-IV (n¼191) Grade III-IV (n¼72) HLA match** 9-10/10 (n¼69) 1.0 1.0 1.0 6-8/10 (n¼246) 1.1 (0.7-1.8) 1.1 (0.5-2.5) 0.7 (0.3-1.5) <6/10 (n¼89) 1.1 (0.7-2.0) 1.4 (0.6-3.3) 1.1 (0.1-2.5)
